rs61886492 — FOLH1 H475Y

Reduces intestinal GCPII enzyme activity by 53%, paradoxically raising circulating folate and lowering homocysteine by slowing folate catabolism in the gut

See your personal result for FOLH1

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

FOLH1 H475Y — The Folate Retention Variant

Before dietary folate from leafy greens, lentils, and liver can enter your bloodstream, it must first be stripped of its glutamate chain. In the intestinal brush border, FOLH1 (folate hydrolase 1, also called GCPII or glutamate carboxypeptidase II11 GCPII or glutamate carboxypeptidase II
GCPII: a type II transmembrane metallopeptidase anchored to jejunal enterocytes; cleaves polyglutamated dietary folates to the absorbable monoglutamate form) performs this essential cleavage step. The H475Y variant at rs61886492 changes a histidine to a tyrosine at position 475 of the enzyme, reducing its catalytic activity by approximately 53% in laboratory models.

What makes this variant scientifically interesting — and clinically relevant — is the direction of its population-level effect: despite the measured reduction in enzyme activity, carriers consistently show higher blood folate and lower homocysteine than non-carriers in large population studies. Understanding why requires looking beyond gut absorption alone.

The Mechanism

The H475Y substitution 22 p.His475Tyr arises from the c.1561C>T change on the coding (minus) strand; on the plus strand of GRCh38 this appears as G>A at chromosome 11 position 49164722 (NC_000011.10:49164721:G:A) alters the spatial configuration of GCPII's substrate-binding region. In transfected COS-7 cells, membranes expressing the H475Y variant showed 53% less folylpolyglutamate carboxypeptidase activity33 53% less folylpolyglutamate carboxypeptidase activity
Devlin AM et al. Glutamate carboxypeptidase II: a polymorphism associated with lower levels of serum folate. Hum Mol Genet, 2000 than wild-type GCPII.

In the gut, GCPII cleaves dietary polyglutamated folates — but it also participates in folate catabolism. The net in-vivo effect may depend on which direction (absorption versus breakdown) dominates in a given tissue context. GCPII is also expressed in the brain, where it cleaves NAAG44 NAAG
N-acetylaspartylglutamate: a neuropeptide acting as a mGluR3 co-agonist; its cleavage releases glutamate and modulates synaptic tone, a neuropeptide that modulates glutamate signaling. In the kidney, GCPII is expressed on proximal tubule cells and may influence folate reabsorption. The combination of these tissue-specific roles means the in-vivo folate phenotype of H475Y reflects a multi-tissue balance rather than gut absorption alone.

The Evidence

The largest and most directly informative study is a Dutch population cohort Lievers et al. 200255 Lievers et al. 2002
Lievers KJA et al. Influence of a GCPII polymorphism on plasma homocysteine, folate and vitamin B12. Atherosclerosis, 2002 examining 190 vascular disease patients and 601 healthy controls. The 1561C>T polymorphism (H475Y) was associated with significantly higher RBC folate and plasma folate concentrations (ANOVA p=0.013, linear trend p=0.03), and TT homozygotes (AA on the plus strand) tended toward lower fasting and post-load homocysteine.

A controlled folate bioavailability trial by Melse-Boonstra et al. 200466 Melse-Boonstra et al. 2004
Melse-Boonstra A et al. Bioavailability of polyglutamyl folic acid. Am J Clin Nutr, 2004 enrolled 180 healthy adults (50–75 years) and found CT carriers had significantly higher baseline erythrocyte and serum folate (p<0.05) than CC homozygotes; however, the bioavailability of supplemental polyglutamyl folic acid was similar across genotypes (64% vs. 70%). This suggests the folate-status advantage arises from expression-level differences rather than altered enzyme kinetics, consistent with the H475Y variant having tissue- and context-specific effects that go beyond simple gut absorption.

The large Norwegian Hordaland Homocysteine Study77 Hordaland Homocysteine Study
Halsted CH et al. Relations of GCPII polymorphisms to folate and homocysteine. Am J Clin Nutr, 2007 confirmed that CT and TT carriers had higher plasma folate and lower total homocysteine concentrations than CC homozygotes. However, it also identified a cognitive nuance: TT homozygotes showed paradoxically lower Symbol Digit Modalities Test scores, particularly among non-drinking women. The authors speculated this could reflect altered NAAG metabolism in the brain — reduced GCPII cleavage preserving NAAG tone in most contexts, but interacting negatively with certain co-factors (alcohol metabolism, B12 status).

In 120 chronic dialysis patients, Fodinger et al. 200388 Fodinger et al. 2003
Fodinger M et al. Effect of GCPII and reduced folate carrier polymorphisms on folate and homocysteine in dialysis patients. J Am Soc Nephrol, 2003 found CT/TT genotypes independently predicted higher RBC folate (p=0.04), even in this high-homocysteine population where B vitamin metabolism is substantially altered.

Practical Actions

For people carrying the AA genotype (two copies of the H475Y T allele), circulating folate levels are typically higher than average. Standard dietary folate intake through whole foods is generally sufficient. The primary clinical consideration is ensuring that the folate advantage translates into adequate methylation capacity — which requires cofactors B12, B6, and riboflavin alongside folate. Monitoring homocysteine confirms that the methylation cycle is operating well.

For heterozygous AG carriers, the folate-raising effect is partial but still present. Supporting the methylation cycle with the full B vitamin complex remains the most practical approach.

The paradox from Halsted 2007 (lower cognitive scores in TT homozygotes) is worth noting but requires replication before strong clinical guidance is possible. Adequate B12 and avoidance of alcohol excess may be especially relevant for AA individuals given the suggested interaction.

Interactions

The H475Y variant sits at the gut absorption step that precedes the methylation cycle. It interacts with downstream methylation variants: MTHFR C677T (rs1801133) and A1298C (rs1801131) determine how efficiently absorbed folate is converted to methylfolate; COMT V158M (rs4680) affects how methyl groups are used. The FOLH1 T484A variant (rs202676) is a separate missense variant in the same gene with different population frequencies and a different direction of effect; the two variants may or may not be in linkage disequilibrium — this has not been formally established. SLC19A1 A80G (rs1051266) controls cellular folate uptake downstream of intestinal absorption.

Nutrient Interactions

folate altered_metabolism
vitamin B12 increased_need

Genotype Interpretations

What each possible genotype means for this variant.

GG Standard Folate Absorber Normal

Normal GCPII activity — standard folate status

You carry two copies of the common G allele at rs61886492 (the histidine-475 form of GCPII). Your intestinal folate hydrolase has normal catalytic activity. Blood folate and homocysteine levels are within the typical population range, assuming adequate dietary folate intake. About 91% of people globally share this genotype; the A allele is rare, particularly in East Asian populations where it is essentially absent.

AG Enhanced Folate Retainer Beneficial

One copy of H475Y — modestly elevated circulating folate expected

Despite reducing GCPII catalytic activity by ~53% in cellular models, the H475Y variant is associated with a net favorable folate phenotype in population studies. The most likely explanation involves expression- level differences across intestinal, renal, and other tissues — the variant may reduce folate catabolism more than it reduces absorption.

A folate bioavailability trial (Melse-Boonstra 2004) found CT carriers had significantly higher baseline erythrocyte and serum folate (p<0.05), with polyglutamyl supplement bioavailability similar to non-carriers. This indicates the folate advantage is not primarily from altered absorption kinetics, but from other regulatory mechanisms.

The Hordaland Homocysteine Study found that CT/TT combined had higher plasma folate and lower total homocysteine. Ensure adequate B12 to support the downstream methylation cycle — higher circulating folate only translates to reduced homocysteine risk when B12 is sufficient.

AA Optimal Folate Retainer High Absorption

Two copies of H475Y — highest folate-retaining genotype in the GCPII pathway

With both GCPII copies carrying the His475Tyr substitution, enzyme activity is substantially reduced. The net in-vivo effect, however, is a favorable folate phenotype: population studies consistently show TT homozygotes have the highest circulating folate and the lowest homocysteine of the three genotypes.

The Hordaland Homocysteine Study (Halsted 2007) introduced one important nuance: TT homozygotes showed paradoxically lower Symbol Digit Modalities Test scores, particularly in female non-drinkers. This may reflect altered NAAG metabolism in the brain — GCPII also cleaves NAAG, a neuropeptide that dampens glutamate receptor tone in synapses important for working memory. Reduced GCPII activity in the brain may alter NAAG levels in ways that interact with alcohol metabolism (ADH1B/ALDH2 variants) and B12 status. This cognitive finding requires replication before it changes clinical guidance.

For AA individuals, the priority is ensuring B12 and other methylation cofactors keep pace with the higher available folate so that circulating folate is efficiently converted to methylfolate and used in the methylation cycle. Homocysteine monitoring confirms this cycle is operating at capacity.